Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate

Background: Lymphatic route is one of the prominent route for improving the poor bioavailability of the drugs which undergoes extensive hepatic first pass metabolism. Nanocarriers (solid lipid nanoparticles) offers a new drug delivery system that could hold great promise for attaining the bioavailability enhancement along with controlled and site specific drug delivery. Objective: The aim of the present research work was to prepare and optimized the Quetiapine fumarate (an antipsychotic drug) loaded solid lipid nanoparticles for lymphatic targeting through intraduodenal administration Method: Thirteen quetiapine fumarate loaded solid lipid nanoparticle formulations were developed using different lipids by Microemulsion technique and optimized by box behnken design. Results: Optimized formulation (Q9) has a mean particle size of 230.38 nm with 75.92% of entrapment efficiency. The percentage drug release after 24 h was found to be 95.81%. Significance difference (P<0.05) was found in the in vitro release data of optimized formulation as to a marketed formulation. In vitro release data of optimized formulation (Q9) was subjected to zero order, first order and Higuchi release model to evaluate the release kinetics. Higuchi model was found to be the best fitted model with highest value of correlation coefficient (R2= 0.999). In vivo studies for optimized solid lipid nanoparticles formulation and drug suspension were performed on male Wistar rats after intraduodenal administration and several pharmacokinetic parameters were determined. AUC (0–∞) of optimized formulation was significantly (P<0.01) more than that of drug suspension. Bioavailability of quetiapine in solid lipid nanoparticles was 2.76 fold increased after intraduodenal administration compared with that of drug suspension. Conclusion: On the basis of results of in vitro study, Q9 formulation was selected as optimized formulation. It exhibited better bioavailability as compared to drug suspension. It can be concluded that solid lipid nanoparticles are potential carrier for improving quetiapine bioavailability through lymphatic delivery.